In studying the mediators of VIP neurotrophism in the central nervous system, two glial proteins have been discovered. Both of these proteins contain short peptides that exhibit femtomolar potency in preventing neuronal cell death from a wide variety of neurotoxic substances. Extension of these peptides to models of oxidative stress or neurodegeneration in vivo have indicated significant efficacy in protection. These peptides, both as individual agents and in combination, have promise as possible protective agents in the treatment of human neurodegenerative disease and in pathologies involving oxidative stress.
Introduction
Two peptides have been identified that exhibit potent neuroprotection. These peptides were discovered while the nature of two glial proteins that are regulated by vasoactive intestinal peptide (VIP) was being investigated. These studies had their origin in investigations of the mechanism of action for VIP neurotrophism in central-nervoussystem cultures [l] . Early studies, which focused on the ability of VIP to block cell death associated with tetrodotoxin, demonstrated that VIP interacted with astrocytes to release substances that provide neuroprotection [2, 3] ; although the secretagogue mechanism was recognized, the identification of the active components was not trivial because so many substances were found to be released from astrocytes after VIP stimulation. Included in this neuroprotective milieu were cytokines, chemokines, protease nexin I and activity-dependent neurotrophic factor (ADNF), the source of one of the peptides [4] . In this paper, a brief description is given of the parent proteins from which the peptides are derived ; then the pharmacology of the two peptides is discussed, with emphasis on their efficacy in model systems and a summary of currently recognized actions that might contribute to their neuroprotective properties.
ADNF : a femtomolar-acting glial protein ADNF was isolated from conditioned medium by three chromatographic steps [S]. PAGE of purified ADNF revealed a 14 kDa protein with a PI of 8.3.
Isolated A D N F had several unusual pharmacological properties : extraordinary potency in preventing neuronal cell death produced by tetrodotoxin and an attenuation of this protective activity with increasing concentrations of ADNF. This is emphasized because similar properties were observed in peptides derived from ADNF. Edmann analysis of A D N F digests revealed an amino acid sequence that was similar, but not identical, to a region in heat shock protein 60 (hsp60). One of the peptides was deduced to have the sequence VLG-GGSALLRSIPA (single-letter codes). This 14-residue peptide, when tested under the same conditions as that of ADNF, showed virtually identical potency and efficacy with that of the parent protein [S] . Structure-activity studies were undertaken that resulted in the identification of a nine-residue peptide : SALLRSIPA, termed ADNF-9 or SAL [6] . Subsequent studies demonstrated that ADNF-9 was even more potent and exhibited a broader range of effective concentrations than the parent protein or the 14-residue peptide. Because purified ADNF is very labile and has limited solubility in aqueous solution when highly concentrated, the study of the peptides has advanced more rapidly than of the parent protein. Current studies continue on determining the complete structure of ADNF.
Pharmacology of ADNF-9
ADNF-9 has been shown to protect cultured neurons from a variety of neurotoxic substances,
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Neuropeptides : From Gene Regulation to Protein Processing including tetrodotoxin, N-methyl-D-aspartate, FeSO,, dopamine, 6-hydroxydopamine, 8-amyloid peptide and gpl20, the envelope protein from HIV [5, 7, 8] . With this range of protective properties, it is not surprising that the pharmacological properties of ADNF-9 are complex and multiple. Evidence will be presented that ADNF-9 has actions that (1) involve both neurons and glia and (2) produce long-term actions with short-term exposure. The latter property suggests that ADNF-9 regulates transcription factors that impinge on survival-related effectors. Beginning with the earliest studies, the survival-promoting activity of ADNF-9 on cerebral cortical cultures comprising both neurons and glia showed high potency and attenuation with increasing concentration ( Figure 1 ). Interestingly, if glia were greatly decreased in the test cultures, a 10000-fold decrease in potency was observed, accompanied by the absence of attenuation with increasing amounts of peptide [6] . These results strongly suggest that interactions with neurons and glia are elicited by treatment with ADNF-9, although it is not known whether these effects are the result of direct actions of the peptide or whether indirect A confounding issue that resides in the use of peptides pharmacologically is that they are rapidly degraded and cleared in complex biological systems. However, with ADNF-9 a useful property is evident: short-term exposure elicits a longterm action; i.e. the peptide does not need to be present to maintain the biological action. Evidence to support this conclusion is shown in Figure 2 . The question is asked: how long does ADNF-9 have to be present to produce a 5-day neuroprotection from apoptotic cell death produced by electrical blockade with tetrodotoxin ? These results indicate that with 2 h of treatment a 5-day period of protection is produced. In addition, the experiments indicate that no biologically active peptide could be detected 15 min after exposure to the cultures. These results strongly suggest that treatment with the peptide initiates long-term changes in the response of the neurons to toxic substances. The most likely explanation of these results is that the peptide produced transcriptional changes, stimulating the expression of relevant cellular enzymes or protein effectors that can produce long-term protection. In support of this idea are the recent results of Glazner et al. [9] , which indicated that 1 h of treatment of hippocampal neurons with ADNF-9 produced a 4-6-fold increase in the activated form of NF-KB. This is particularly relevant in that this transcription factor has been shown to induce Mn superoxide dismutase and calbindin, a protein that aids in Ca2+ homoeostasis [lo] . Several other recent studies also have addressed the mechanism of ADNF-9. In rat hippocampal cultures, ADNF-9 was shown to inhibit the formation of reactive oxygen species and the formation of mitochondria1 peroxynitrite after oxidative stress [7] . In addition, studies conducted with synpatosomes indicated that both basal transport of glucose and glutamate transport were enhanced after treatment with ADNF-9 [l 11. Furthermore, oxidative impairment of glucose and glutamate transport produced by 8-amyloid and FeSO, were prevented by ADNF-9. In other mechanistic studies, ADNF-9 was shown to increase the expression of hsp60 in cerebral cortical neurons in cell cultures after 24 h [12] . In addition, ADNF-9 can prevent both cell death and the depletion of hsp60 produced by Pamyloid peptide.
Activity-dependent neuroprotective protein (ADNP)
The source of the second neuroprotective peptide was ADNP [13] . This survival-promoting protein was expression cloned from a cDNA library from P19 (a neuroglial differentiated carcinoma cell line). Antiserum prepared against ADNF-14 was used to identify clones of interest. Although it was clear from the beginning that ADNP was not ADNF, this protein was pursued because bacteria containing the ADNP clone exhibited remarkable neuroprotection at very high dilutions and because it was a novel sequence. Very importantly, ADNP contained a sequence (NAPVSIPQ) that was similar to that of ADNF-9. Furthermore, mRNA for ADNP was detected in astrocytes, and treatment with VIP produced a significant increase in ADNP expression. Thus ADNP was concluded to be a potentially important protective agent in its own right. ADNP is an 828-residue protein with an apparent PI of 5.99. Interesting features of this protein included a glutaredoxin active site and a Zn2+-binding domain. Most relevant for this discussion is the discovery that NAPVSIPQ (NAP) exhibited neuroprotective actions. As shown in Figure 3 , treatment with NAP, like that with ADNF-9, prevented neuronal cell death associated with electrical blockade. Although both peptides exhibited this protection, NAP produced a bimodal dose response, suggestive of multiple mechanisms. Further studies in vitro showed that NAP protected cerebral cortical neurons from a variety of substances including P-amyloid peptide, N-methyl-D-aspartate, gpl20, dopamine, 6-hydroxydopamine and H,O, [8, 13, 14] .
An important area of application in which peptides often fail is their efficacy in models of degeneration in vivo. However, NAP has been shown to be effective in preventing short-term memory deficits and in accelerating developmental reflexes in apolipoprotein E-deficient mice [13] . Furthermore, intranasal application of NAP to rats treated with a cholinotoxin improved their performance in a spatial learning model [15] . Although the mechanism through which NAP provides neuroprotection and improved performance in these behavioural tests is not yet known, it Treatment was for 5 days and neuronal counts were conducted as described in Figure I . The broken line shows cell counts obtained for control cuttures. 
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